2-(2,4-dichlorophenoxy)ethyl chloride | 64010-13-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,4-dichlorophenoxy)ethyl chloride
• 英文别名: 1-(2-chloroethoxy)-2,4-dichlorobenzene；2,4-Dichlorphenyl-β-chloraethylaether；1-Chlor-2-(2,4-dichlor-phenoxy)-ethan；(2-chloro-ethyl)-(2,4-dichloro-phenyl)-ether；(2-Chlor-aethyl)-(2,4-dichlor-phenyl)-aether；2,4-dichloro-1-(2-chloroethoxy)benzene；2-Chlor-1-(2.4-dichlor-phenoxy)-aethan；2.4-Dichlor-1-(2-chlor-aethoxy)-benzol；2-(2.4-Dichlor-phenoxy)-aethylchlorid
• CAS: 64010-13-5
• 化学式: C₈H₇Cl₃O
• 分子量: 225.502
• InChiKey: LUDNUXFYQGGBBD-UHFFFAOYSA-N

物化性质

• 熔点：
  31 °C
• 沸点：
  134-135 °C(Press: 5.5 Torr)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2,4-dichlorophenoxy)ethyl chloride 在 盐酸 作用下， 生成 4-(2,4-Dichloro-phenoxy)-2-(2,4-dichloro-phenyl)-butyric acid methyl ester
  参考文献：
  名称：

  抗霉菌咪唑。3.1- [2-（芳氧基烷基）-2-苯基乙基] -1H-咪唑的合成和抗真菌性能。

  摘要：

  DOI：

  10.1021/jm00221a033
• 作为产物：
  描述：

  2,4-二氯酚 在 吡啶 、 氯化亚砜 、 sodium hydroxide 作用下， 以 氯仿 、 水 为溶剂， 生成 2-(2,4-dichlorophenoxy)ethyl chloride
  参考文献：
  名称：

  Aryl ethers of 4-[(2-hydroxyethyl)sulfanyl]pyrimidine derivatives: Pathways of synthesis and fungicidal activity of their salt forms

  摘要：

  2-Amino-4-[(2-aryloxyethyl)sulfanyl]-6-methylpyrimidines were obtained by S-alkylation of 2-amino-6-methylpyrimidin-4(3H)-thione with 2-aryloxyethyl chlorides. Since 2-amino-4-[(2-chloroethyl)sulfanyl]-6-methylpyrimidine is prone to in situ intramolecular cyclization it cannot be used in Claisen reaction. The bromination of the target compounds provided 5-bromo derivatives; some of their hydrochlorides exhibited fungicidal activity.

  DOI：

  10.1134/s1070363216060098

文献信息

• HYDROLYSIS AND HYDRAZINOLYSIS OF ESTERS OF N,N-DIMETHYLDITHIOCARBAMIC ACID: A METHOD FOR THE PREPARATION OF MERCAPTANS
  作者：Marshall Kulka

  DOI：10.1139/v56-142

  日期：1956.8.1

  mercaptans from alkyl and aralkyl chlorides. This consists of the condensation of sodium N,N-dimethyl-dithiocarbamate with halides followed by alkaline hydrolysis or hydrazinolysis of the resulting N,N-dimethyldithiocarbamates (IV). In the hydrazinolysis of IV, an insoluble solid by-product was formed which was identified as 3-hydrazino-4-amino-5-mercapto-4,1,2-triazole. Although this method was found to have

  已开发出一种由烷基和芳烷基氯化物制备硫醇的方法。这包括 N,N-二甲基二硫代氨基甲酸钠与卤化物缩合，然后碱水解或肼解所得 N,N-二甲基二硫代氨基甲酸酯 (IV)。在IV的肼解过程中，形成了一种不溶性固体副产物，其被鉴定为3-肼基-4-氨基-5-巯基-4,1,2-三唑。虽然发现这种方法具有广泛的范围，但遇到了一些失败。IV 的硝基衍生物对碱或肼敏感，并且在尝试降解时仅产生焦油。发现 β-苯氧乙基 N,N-二甲基二硫代氨基甲酸酯 (IX) 具有不稳定的烷基 - 氧键，因此在碱或肼存在下，仅形成相应的酚类。
• [EN] SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS<br/>[FR] DERIVES DE GLYCINE SUBSTITUES SERVANT DE MEDICAMENTS
  申请人：PFIZER LTD

  公开号：WO2004016583A1

  公开（公告）日：2004-02-26

  The compounds of formula (I) are substituted glycine derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. Formula (I) wherein R' is hydroxycarbonyl, a carboxylic acid biostere or prodrug thereof; R3, R3a, R2 and R2a are independently selected from H, C1-C6 alkyl, and Cl-C6 alkoxy Cl-C6 alkyl.

  公式(I)的化合物是取代甘氨酸衍生物，可用于治疗癫痫、晕厥发作、运动减少、颅脑疾病、神经退行性疾病、抑郁症、焦虑症、恐慌症、疼痛、关节炎、神经病理学疾病、睡眠障碍、内脏疼痛疾病和胃肠疾病。包括用于制备最终产品和在过程中有用的中间体的方法。还包含含有一种或多种化合物的药物组合物。公式(I)中，R'是羟碳酰基，羧酸的生物立体异构体或前药；R3、R3a、R2和R2a独立地选自H、C1-C6烷基和Cl-C6烷氧基Cl-C6烷基。
• 2,3-DIHYDROBENZO(<i>f</i>)-l,4-OXATHIEPIN AND DERIVATIVES
  作者：Marshall Kulka

  DOI：10.1139/v55-173

  日期：1955.9.1

  A method has been developed for the synthesis of a new heterocyclic system III. When 2-β-chloroethoxybenzyl chloride (XI) was heated with thiourea in alcohol solution, S-(2-β-chloroethoxybenzyl)isothiuronium chloride (XII) was formed which on cleavage with aqueous alkali in high dilution yielded 2,3-dihydrobenzo(f)-1,4-oxathiepin (III). Derivatives of III with substituents such as methyl, t-butyl, chlorine, and nitro in the 7 and 9 positions were prepared in high yields from the corresponding substituted 2-β-chloroethoxybenzyl chlorides. The presence of substituents in the position ortho to the chloroethoxy group of XII had no retarding effect on the cyclization to XIV.

  已开发出一种合成新杂环系统 III 的方法。当 2-β-氯乙氧基苄氯（XI）在醇溶液中与硫脲加热时，形成了 S-(2-β-氯乙氧基苄)异硫脲盐酸盐（XII），在高稀释条件下与水性碱裂解，生成了2,3-二氢苯并(f)-1,4-噁硫杂环（III）。通过对应的取代的 2-β-氯乙氧基苄氯制备了 III 的衍生物，这些衍生物在 7 和 9 位置带有甲基、叔丁基、氯和硝基等取代基，并且产率很高。XII 的氯乙氧基基团正交位上的取代基对生成 XIV 的环化反应没有延缓作用。
• Substituted glycine derivatives for use as medicaments
  申请人：——

  公开号：US20040092498A1

  公开（公告）日：2004-05-13

  The compounds of formula (I) are substituted glycine derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. 1 wherein R 1 is hydroxycarbonyl, a carboxylic acid biostere or prodrug thereof; R 3 , R 3a , R 2 and R 2a are independently selected from H, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy C 1 -C 6 alkyl; Z is; (i) a C-linked, 5 membered heterocycloalky or heteroaryl substituted with C 1 -C 6 alkyl or fused with C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, or monocyclic heteroaryl, wherein the fused ring is optionally substituted with one or two substituents selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, perfluoro C 1 -C 6 alkyl, perfluoro C 1 -C 6 alkoxy, cyano, C 1 -C 6 alkyl amino, C 1 -C 6 alkyl thio, C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, and monocyclic heteroaryl; or (ii) the group; 2 wherein R 4 and R 4a are independently H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy or C 1 -C 6 alkoxy C 1 -C 6 alkyl; R 5 is C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, 4-12 membered heterocycloalkyl, aryl or heteroaryl and R 5 is optionally substituted with one or two substituents selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, perfluoro C 1 -C 6 alkyl, perfluoro C 1 -C 6 alkoxy, cyano, C 1 -C 6 alkyl amino, di-C 1 -C 6 alkyl amino, amino C 1 -C 6 alkyl, C 1 -C 6 alkyl amino C 1 -C 6 alkyl, di-C 1 -C 6 alkyl amino C 1 -C 6 alkyl, C 1 -C 6 alkyl thio, C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; and either; (i) Y is S, O, NH or CH 2 and X is a direct link or C 1 -C 2 alkyl optionally substituted with C 1 -C 6 alkyl or di-C 1 -C 6 alkyl or 1-4 fluorine atoms; or (ii) X is S, O, CH 2 or NH and Y is C 1 -C 2 alkyl optionally substituted with C 1 -C 6 alkyl or di-C 1 -C 6 alkyl or 1-4 fluorine atoms.

  公式（I）的化合物是取代的甘氨酸衍生物，用于治疗癫痫，晕厥发作，低动力症，颅内疾病，神经退行性疾病，抑郁症，焦虑症，惊恐症，疼痛，关节炎，神经病理学疾病，睡眠障碍，内脏疼痛疾病和胃肠疾病的治疗。包括制备最终产品和在过程中有用的中间体的过程。还包括含有一种或多种化合物的制药组合物。 其中，R1是羟基甲酰，羧酸生物立体异构体或其前药; R3，R3a，R2和R2a独立选择自H，C1-C6烷基和C1-C6烷氧基C1-C6烷基; Z是; (i) C-连接的，5个成员的杂环烷基或杂环芳基，用C1-C6烷基或与C3-C8环烷基融合，4-8个成员的杂环烷基，苯基或单环杂芳基取代，其中融合环可选地取代为卤素，C1-C6烷基，C1-C6烷氧基，全氟C1-C6烷基，全氟C1-C6烷氧基，氰基，C1-C6烷基氨基，C1-C6烷基硫基，C3-C8环烷基，4-8个成员的杂环烷基，苯基和单环杂芳基的两个取代基中的一种; 或 (ii) 该组; 其中，R4和R4a独立为H，C1-C6烷基，C1-C6烷氧基或C1-C6烷氧基C1-C6烷基; R5是C1-C6烷基，C3-C12环烷基，4-12个成员的杂环烷基，芳基或杂芳基，R5可选地取代为卤素，C1-C6烷基，C1-C6烷氧基，全氟C1-C6烷基，全氟C1-C6烷氧基，氰基，C1-C6烷基氨基，二C1-C6烷基氨基，氨基C1-C6烷基，C1-C6烷基氨基C1-C6烷基，二C1-C6烷基氨基C1-C6烷基，C1-C6烷基硫基，C3-C8环烷基，4-8个成员的杂环烷基，苯基和单环杂芳基的两个取代基中的一种; 并且要么; (i) Y是S，O，NH或CH2，X是直接链接或C1-C2烷基，可选地取代为C1-C6烷基或二C1-C6烷基或1-4个氟原子; 或 (ii) X是S，O，CH2或NH，Y是C1-C2烷基，可选地取代为C1-C6烷基或二C1-C6烷基或1-4个氟原子。
• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。